silybin has been researched along with gefitinib in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 4 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Barrajón-Catalán, E; Bonavia, R; Bosch-Barrera, J; Corominas-Faja, B; Cufí, S; Cuyàs, E; Joven, J; Martin-Castillo, B; Menendez, JA; Micol, V; Oliveras-Ferraros, C; Segura-Carretero, A; Vazquez-Martin, A; Visa, J | 1 |
Han, J; Jeon, M; Jung, T; Kil, WH; Kim, S; Lee, J; Lee, JE; Nam, SJ; Oh, SJ | 1 |
Choi, SJ; Gu, HR; Han, CJ; Jeong, JH; Kim, J; Kim, YC; Kim, YJ; Lee, JC; No, SH; Noh, GY; Park, SC; Yang, KY | 1 |
4 other study(ies) available for silybin and gefitinib
Article | Year |
---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Silibinin meglumine, a water-soluble form of milk thistle silymarin, is an orally active anti-cancer agent that impedes the epithelial-to-mesenchymal transition (EMT) in EGFR-mutant non-small-cell lung carcinoma cells.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antioxidants; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Chromatography, High Pressure Liquid; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Humans; Meglumine; Mice; Mice, Inbred NOD; Plant Extracts; Protein Kinase Inhibitors; Quinazolines; Seeds; Silybin; Silybum marianum; Silymarin; Tandem Mass Spectrometry; Xenograft Model Antitumor Assays | 2013 |
Induction of fibronectin in response to epidermal growth factor is suppressed by silibinin through the inhibition of STAT3 in triple negative breast cancer cells.
Topics: Antineoplastic Agents; Antioxidants; Cell Line, Tumor; Female; Fibronectins; Gefitinib; Humans; MCF-7 Cells; Phosphorylation; Quinazolines; Signal Transduction; Silybin; Silymarin; Triple Negative Breast Neoplasms; Tyrphostins | 2014 |
Combined treatment with silibinin and either sorafenib or gefitinib enhances their growth-inhibiting effects in hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Down-Regulation; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Silybin; Silymarin; Sorafenib | 2015 |